ProsTAV, a clinically useful test in prostate cancer: an extension study

Area of Science:

• Urology
• Oncology
• Biomarker Discovery

Background:

• Prostate cancer (PCa) diagnosis often involves invasive biopsies.
• Accurate risk stratification is crucial for appropriate biopsy decisions.

Purpose of the Study:

• To evaluate the clinical performance of ProsTAV, a blood-based test, for supporting prostate biopsy decisions.
• To assess ProsTAV's utility in diagnosing suspicious prostate cancer (PCa).

Main Methods:

• Prospective observational pragmatic study involving 251 patients with PSA levels 3-10 ng/ml.
• ProsTAV (telomere associate variables) blood test performance was analyzed.
• Sensitivity, specificity, and predictive values were calculated; potential biopsy avoidance was assessed.

Main Results:

• ProsTAV demonstrated an AUC of 0.7 with 90% sensitivity and 27% specificity for significant PCa.
• The test achieved a negative predictive value of 74%, suggesting it could help avoid 27% of biopsies.
• Combined use with MRI showed potential benefits in the diagnostic pathway.

Conclusions:

• ProsTAV enhances the prediction of significant prostate cancer in men with PSA levels between 3-10 ng/ml.
• This blood test can serve as a complementary tool to optimize the prostate cancer diagnostic pathway.
• Further research may solidify ProsTAV's role in reducing unnecessary prostate biopsies.